Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Tirzepatide weight loss for MRD-positive early breast cancer

Phase 2 trial of tirzepatide in early breast cancer with molecular residual disease. Registry primary outcomes are ctDNA efficacy and distant disease-free survival. ClinicalTrials.gov lists the study as recruiting.

Baylor Research Institute